...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Reports of Exempt Distribution
2023-01-31
40,833 Common Shares @80 cents CAN,  no warrants
Total value $32,707.00 CAN
Out of USA
 

2023-02-10

2- Convertible Notes for $133,620 each CAN / Convertible to Common shares @80 cents CAN / No timeline  given
+ 150 Warrants @80 cents CAN expire 2028-02-10. Out of USA & Germany
Total value $ 267,240.00 CAN
 
2023-02-24
2- Convertable Notes for $204,330 each CAN / Convertable to Common Shares @ 82 cents CAN/ No timeline given
No warrants. Out of the USA and Germany
Total Value $408,660.00 CAN
 
2023-03-01
179.945 Common Shares @ $1.36 CAN 
+ 1/2 warrants @ $1.36 CAN expire 2023-11-14.
10,796 Common Shares @ $1.36 CAN 
No warrants. Out of Hong Kong, BC, & Alberta
Total Value = $259,407.76 CAN
 
In total = $968,014.76 CAN
 


Interest in Zenith Capital Corp., "ZHCLF" builds.
 
 
Koo

 

Share
New Message
Please login to post a reply